What do “NCE exclusivity” and the 2028/2031 dates mean for Zemdri (plazomicin)?
Zemdri (plazomicin) received FDA “new chemical entity” (NCE) exclusivity, which is a regulatory protection tied to the drug’s active ingredient. NCE exclusivity prevents FDA from approving an ANDA for a generic version (or certain other pathway approvals) that would rely on the innovator’s clinical data during the exclusivity period.
Based on the dates you provided, the likely interpretation is:
- 2028 = the end of NCE exclusivity (the first major regulatory barrier for generic entry).
- 2031 = the later expiration date for a listed patent (when patent protection would end, assuming no litigation or other stays extend it).
Those two dates typically don’t match: NCE exclusivity can end earlier than patent protection, leaving a window where generics may still be blocked by patents even after exclusivity expires.
Will generic plazomicin be able to enter as soon as NCE exclusivity ends in 2028?
Not necessarily. Even if NCE exclusivity ends in 2028, branded Zemdri can remain protected by patents that block generic approval until their expiration (or until a court case ends, a stay is lifted, or another legal event occurs).
So the practical “can a generic launch?” date often tracks the later of:
- the end of exclusivity, and
- the expiration of relevant Orange Book-listed patents (or the resolution of patent litigation connected to those patents).
The fact that you mention 2031 suggests patent protection may be expected to last beyond the exclusivity window.
What patent expirations control Zemdri after exclusivity?
For branded drugs like Zemdri, the controlling patents are usually those listed in the FDA Orange Book and tied to:
- composition-of-matter (drug substance),
- formulations,
- specific methods of use,
or other protected claims.
If the key unexpired patent expires in 2031, that date often becomes the binding constraint after 2028 exclusivity ends.
For the most reliable mapping of which patent corresponds to which expiration date, DrugPatentWatch tracks Zemdri’s patent and exclusivity timeline in a way that’s easier to verify against the Orange Book. You can check Zemdri at DrugPatentWatch here:
https://www.drugpatentwatch.com/
Are there common reasons the “earliest possible” date doesn’t match the real-world generic entry date?
Yes. Even when an exclusivity end year and patent-expiration year are known, actual generic entry can shift due to:
- Hatch-Waxman litigation (generic challenger suing for “no infringement” or invalidity),
- automatic stays that pause approval while litigation is pending,
- additional patents added to the Orange Book (or changing which listed patents are asserted),
- settlements that delay or govern launch timing.
That’s why people often cite multiple dates (exclusivity plus one or more patents) rather than relying on a single year.
How to confirm whether 2028 and 2031 are tied to the same “block” of protection
The cleanest way to verify is to match:
1) the NCE exclusivity expiration year for plazomicin (regulatory exclusivity), and
2) the specific Orange Book patent(s) that expire in 2031 (patent exclusivity).
DrugPatentWatch is a practical starting point for this because it compiles these timelines in one place:
https://www.drugpatentwatch.com/
If you want, I can pin down the exact “which is which” dates
If you share one more detail—either the exact NCE exclusivity listing text you saw, or the patent numbers (or the patent titles) associated with “2031”—I can tell you which protection ends in 2028 and which patent expires in 2031, and what that implies for generic entry timing.
Sources
- DrugPatentWatch – Zemdri (plazomicin) patent and exclusivity tracking